A Novel and Domain-Specific Document Clustering and Topic Aggregation Toolset for a News Organisation

Large collections of documents are becoming increasingly common in the news gathering industry. A review of the literature shows there is a growing interest in datadriven journalism and specifically that the journalism profession needs better tools to understand and develop actionable knowledge from large document sets. On a daily basis, journalists are tasked with searching a diverse range of document sets including news gathering services, emails, freedom of information requests, court records, government reports, press releases and many other types of generally unstructured documents. Document clustering techniques can help address problems of understanding the ever expanding quantities of documents available to journalists by finding patterns within documents. These patterns can be used to develop useful and actionable knowledge which can contribute to journalism. News articles in particular are fertile ground for document clustering principles. Term weighting schemes assign importance to terms within a document and are central to the study of document clustering methods. This study contributes a review of the dominant and most commonly used term frequency weighting functions put forward in research, establishes the merits and limitations of each approach, and proposes modifications to develop a news-centric document clustering and topic aggregation approach. Experimentation was conducted on a large unstructured collection of newspaper articles from the Irish Times to establish if the newly proposed news-centric term weighting and document similarity approach improves document clustering accuracy and topic aggregation capabilities for news articles when compared to the traditional term weighting approach. Whilst the experimentation shows that that the developed approach is promising when compared to the manual document clustering effort undertaken by the three journalist expert users, it also highlights the challenges of natural language processing and document clustering methods in general. The results may suggest that a blended approach of complimenting automated methods with human-level supervision and guidance may yield the best results

Interactive book-reading to improve inferencing abilities in kindergarten classrooms : a clinical project

Inferencing abilities are crucial to development of reading comprehension. However, few studies addressed those abilities in interventions promoting early literacy skills, especially in kindergartners. The aim of this study was to measure the efficacy of an interactive book-reading intervention targeting inferencing abilities, delivered by a school-based speech-language pathologist (SLP) in whole group kindergarten classes. Two hundred and forty-nine 5-year-old kindergartners from low socio-economic settings were quasi-randomly assigned to either one of the experimental groups (EG1 and EG2) or an active control group (CG). EG1 received a 7-week interactive book-reading intervention followed by a 7-week period where it was up to the teachers to implement aspects of the intervention in their teaching or not. EG2 received the 7-week interactive book-reading intervention only and the active control group received an initial workshop only. Three subtests targeting (1) causal inferences during book-reading, (2) causal inferences in a formal task, and (3) referential inferences in a formal task were performed at pre- and post-intervention assessments. There was a significant Time × Group interaction effect for the first subtest indicating an advantage for EG1 compared to CG over time. EG2 appeared as an intermediary group as its results were not different from EG1 and showing only a trend toward significance (p = 0.064) when compared to CG. There was no significant Time × Group interaction effect for the second subtest. A significant Time × Group interaction effect was present for the third subtest, EG1 and EG2 showing larger improvement than CG

Does student loan debt deter higher education participation? New evidence from England

Research among prospective UK undergraduates in 2002 found that some students, especially from low social classes, were deterred from applying to university because of fear of debt. This paper investigates whether this is still the case today in England despite the changing higher education landscape since 2002. The paper describes findings from a 2015 survey of prospective undergraduates and compares them with those from the 2002 study. We find that students’ attitudes to taking on student loan debt are more favorable in 2015 than in 2002. Debt averse attitudes remain much stronger among lower-class students than among upper-class students, and more so than in 2002. However, lower-class students did not have stronger debt averse attitudes than middle-class students. Debt averse attitudes seem more likely to deter planned higher education participation among lower-class students in 2015 than in 2002

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Background Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS). Methods/design FLAIR is a phase III, multicentre, randomised, controlled, open, parallel-group trial in patients with previously untreated CLL. A total of 754 participants will be randomised on a 1:1 basis to receive standard therapy with FCR or IR. Participants randomised to FCR will receive a maximum of six 28-day treatment cycles. Participants randomised to IR will receive six 28-day cycles of rituximab, and ibrutinib taken daily for 6 years until minimal residual disease (MRD) negativity has been recorded for the same amount of time as it took to become MRD negative, or until disease progression. The primary endpoint is PFS according to the International Workshop on CLL (IWCLL) criteria. Secondary endpoints include: overall survival; proportion of participants with undetectable MRD; response to therapy by IWCLL criteria; safety and toxicity; health-related quality of life (QoL); and cost-effectiveness. Discussion The trial aims to provide evidence for the future first-line treatment of CLL patients by assessing whether IR is superior to FCR in terms of PFS, and whether toxicity rates are favourable. Trial registration ISRCTN01844152. Registered on 8 August 2014, EudraCT number 2013-001944-76. Registered on 26 April 2013

Head and neck cancer in the UK: what was the stage before COVID-19? UK cancer registries analysis (2011-2018)

Introduction: People who present with more advanced stage head and neck cancer (HNC) are associated with poorer outcomes and survival. The burden and trends of advanced stage HNC are not fully known at the population level. The UK national cancer registries routinely collect data on HNC diagnoses. Aims: To describe trends in stage of diagnosis of HNCs across the UK before the COVID-19 pandemic. Methods: Aggregated HNC incidence data were requested from the national cancer registries of the four UK countries for the ten most recent years of available data by subsite and American Joint Commission on Cancer stage at diagnosis classification. Additionally, data for Scotland were available by age group, sex and area-based socioeconomic deprivation category. Results: Across the UK, rates of advanced stage HNC had increased, with 59% of patients having advanced disease at diagnosis from 2016-2018. England had a lower proportion of advanced disease (58%) than Scotland, Wales or Northern Ireland (65-69%) where stage data were available. The completeness of stage data had improved over recent years (87% by 2018). Conclusion: Prior to the COVID-19 pandemic, diagnoses of HNC at an advanced stage comprised the majority of HNCs in the UK, representing the major challenge for the cancer healthcare system

Dense molecular gas in quasar host galaxies: a search for HCN emission from BR B1202-0725 at z=4.695

We report on the results of a search using the VLA for redshifted HCN(1-0) emission from the host galaxy of BR B1202-0725, an optically luminous quasar at z=4.695. The host galaxy emits strongly in the rest-frame far-infrared, and shows characteristics very similar to that of more local, ultraluminous infrared galaxies, in which a significant fraction of the far-infrared emission is powered by star formation. We find a 3-sigma upper limit to the HCN(1-0) emission of 4.9 x 10^10 K kms^-1 pc^2, assuming a lambda-cosmology. This limit is consistent with correlations derived from measurements of the HCN, CO, and far-infrared emission for a sample of more local galaxies, including starbursts (Solomon et al, 1992a)

Using email reminders to engage physicians in an Internet-based CME intervention

BACKGROUND: Engaging practicing physicians in educational strategies that reinforce guideline adoption and improve the quality of healthcare may be difficult. Push technologies such as email offer new opportunities to engage physicians in online educational reinforcing strategies. The objectives are to investigate 1) the effectiveness of email announcements in engaging recruited community-based primary care physicians in an online guideline reinforcement strategy designed to promote Chlamydia screening, 2) the characteristics of physicians who respond to email announcements, as well as 3) how quickly and when they respond to email announcements. METHODS: Over a 45-week period, 445 recruited physicians received up to 33 email contacts announcing and reminding them of an online women's health guideline reinforcing CME activity. Participation was defined as physician log-on at least once to the website. Data were analyzed to determine participation, to compare characteristics of participants with recruited physicians who did not participate, and to determine at what point and when participants logged on. RESULTS: Of 445 recruited physicians with accurate email addresses, 47.2% logged on and completed at least one module. There were no significant differences by age, race, or specialty between participants and non-participants. Female physicians, US medical graduates and MDs had higher participation rates than male physicians, international medical graduates and DOs. Physicians with higher baseline screening rates were significantly more likely to log on to the course. The first 10 emails were the most effective in engaging community-based physicians to complete the intervention. Physicians were more likely to log on in the afternoon and evening and on Monday or Thursday. CONCLUSIONS: Email course reminders may enhance recruitment of physicians to interventions designed to reinforce guideline adoption; physicians' response to email reminders may vary by gender, degree, and country of medical training. Repetition of email communications contributes to physician online participation

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of the line of therapy. Methods/design: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) is a seamless phase II/III, multi-centre, randomised, controlled, open, parallel-group trial for patients with CLL who have recently responded to chemotherapy. Participants will be randomised to receive either obinutuzumab (GA-101) consolidation or no treatment (as is standard). The phase II trial will assess safety and short-term efficacy in order to advise on continuation to a phase III trial. The primary objective for phase III is to assess the effect of consolidation therapy on progression-free survival (PFS). One hundred eighty-eight participants are planned to be recruited from forty research centres in the United Kingdom. Discussion: There is evidence that achieving MRD eradication with alemtuzumab consolidation is associated with improvements in survival and time to progression. This trial will assess whether obinutuzumab is safe in a consolidation setting and effective at eradicating MRD and improving PFS. Trial registration: ISRCTN, 64035629. Registered on 12 January 2015. EudraCT, 2014-000880-42. Registered on 12 November 2014